Mystical experience as clinical endpoint

Researchers are treating ‘mystical’ or transcendent subjective experiences (measured by questionnaires and interview scales) as measurable outcomes in psychedelic clinical trials, not merely anecdotes. That reframes efficacy from symptom reduction alone to transformational, meaning‑centered endpoints that sit awkwardly with secular clinical metrics. — If medicine accepts mystical‑style outcomes, regulators, insurers, and clinicians will have to reconcile subjective spiritual claims with standards of evidence, consent, and scaling of treatments.